Adrienne W. Scott, MD, FASRS; Justine Cheng, MD; Hong-Uyen Hua, MD; Sherrol A. Reynolds OD, FAAO, FNAP Melissa Barnett, OD, FAAO, FSLS, FBCLA; Cecelia Koetting, OD, FAAO, DipABO; Quan Đông Nguyễn, MD, ...
Multimodal imaging, including OCT and FAF, is crucial for differentiating between AMD and IRDs, enabling precise diagnosis.
NDA submissions for NCX 470 are planned for the first half of 2026 in the US, with China following shortly after. NCX 470 is ...
They explore how rapid symptom relief affects satisfaction, outline current unmet needs in DED treatment, and share guidance ...
Collaboration between specialists is essential to optimize outcomes and explore regenerative approaches for effective ...
“TED is 5 times more prevalent in women, and because of that, men are often overlooked for the diagnosis,” Nijm said. The ...
The US Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for ...
Panelists discuss how the 8-mg aflibercept formulation improves drying efficacy, extends dosing intervals, and reduces burden ...
Panelists discuss how higher-dose and dual-pathway anti-VEGF agents enable longer intervals, improved fluid control, and more ...
Argenx SE has discontinued the phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED ...
Aviceda Therapeutics has released topline results from its phase 2b study, SIGLEC, evaluating AVD-104 in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback